Our Team
Leading Pacific Marine Biotech to discover and deliver to the world our cutting edge, medical discoveries is a global team of professionals and staff.
Board of Directors
Advisory Board
Medical Advisors
Legal Advisor
Suppression of Human Multiple Myeloma Cell Growth by TBL-12 in Combination with low doses of Velcade:
Multiple myeloma (MM) is characterized by the latent accumulation of plasma cells in the bone marrow. As the side effects due to drugs that are currently in use are largely complex, targeting MM with natural agents in combination with FDA approved drugs seems to be a novel approach to overcome the side effects. Methods: In this study we tested the efficacy of proteasome inhibitor Velcade (Bortezomib) in combination with TBL-12, (an extract from Sea Cucumber, Unicorn Pacific Corporation) in human myeloma cells that are IL-6- dependent and-independent.
Fixed Dose Study on Toxicity, Nova Southeastern University
Results: Under the conditions of the test, no deaths were reported, and all animals were observed to be “bright, alert, and responsive” (BAR). Detailed observation logs and weight logs are provided in the report. Some necropsy findings included mild/moderate mottling of the lungs in some animals, cortical cysts on the kidney in a couple of animals, and the presence of a gavage needle in one animal’s esophagus and stomach at the 9g/kg dose level.